Apple Rallies Most Since May on Strong iPhone Pre-Order Data

(Bloomberg) — Apple Inc. shares rallied the most since May as pre-order data showed the iPhone 14 Pro Max was the best selling model, surpassing what the older version did in a similar timeframe.

Shares of the tech giant rose 3.9%, their biggest one-day gain since May 27, and the stock closed above its 200-day moving average for the first time since August. Analysts from JPMorgan to Barclays wrote that the data point to strong demand for the latest mobile phone series, which was unveiled at its product launch event last week.

“Pre-order data shows that the iPhone 14 Pro Max is the best-selling model, and that it is doing better than the iPhone 13 Pro Max did at this point,” KGI Securities analyst Christine Wang wrote in a report. The pricing of the iPhone 14 series is positive for its future sales, she added.

At its biggest product launch of the year, Apple introduced the iPhone 14, fresh AirPods Pro earbuds and new Apple Watch models. The iPhone retains the general look of the older version while getting camera enhancements and a long-anticipated satellite-messaging feature. The bulk of the iPhone upgrades are coming to the higher-end Pro line. Those devices will get a 48-megapixel camera and a screen that’s capable of always staying on in a low-power mode, similar to recent versions of the Apple Watch.

Apple is the top performing megacap technology stock this year, because investors have faith in its ability to tap into its more than 1 billion customers to earn more on its services including apps, video, fitness and gaming subscriptions. The next catalyst for the stock will be earnings for the September quarter, which is expected in late October.

Its shares are about 8% lower this year compared with the Nasdaq 100 Index, which has slumped about 22%. About 96% of the 50 analysts covering the stock recommend either buying Apple shares or holding on to their positions, while only two suggest selling, according to data compiled by Bloomberg.

 

More stories like this are available on bloomberg.com.

©2022 Bloomberg L.P.

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More